Table 3 Ranked criteria reported by physicians for assessing fibromyalgia severity (N = 28) based on the open-ended question "When you assess the severity of fibromyalgia as a condition in your patients, what are the top 5 items (specific symptoms, specific physical findings, specific abnormal lab findings, etc.) that influence your decision-making?"
From: Toward characterization and definition of fibromyalgia severity
Ranked criteria, n (%) of responses | ||||
|---|---|---|---|---|
#1 | #2 | #3 | #4 | #5 |
Pain*, 17 (60.7) | Functional disability, 6 (21.4) | Fatigue, 4 (14.3) | Functional disability, 4 (14.3) | Fatigue severity, 3 (10.7) |
FIQ, 3 (10.7) | Pain, 4 (14.3) | Functional disability, 3 (10.7) | Presence of comorbidities, 4 (14.3) | Duration of symptoms, 1 (3.6) |
Functional disability, 2 (7.1) | Sleep disruption, 4 (14.3) | Sleep disruption, 3 (10.7) | Sleep disruption, 3 (10.7) | Pain, 1 (3.6) |
Tender points, 2 (7.1) | Duration of symptoms, 3 (10.7) | Presence of comorbidities, 3 (10.7) | Fatigue severity, 2 (7.1) | Sleep disruption, 1 (3.6) |
Fatigue, 1 (3.6) | Tender points, 2 (7.1) | Pain, 2 (7.1) | Pain, 1 (3.6) | Global assessment,1 (3.6) |
QoL, 1 (3.6) | Presence of comorbidities, 2 (7.1) | Tender points, 2 (7.1) | QoL, 1 (3.6) | Tender points, 1 (3.6) |
Sleep disruption, 1 (3.6) | Fatigue, 1 (3.6) | QoL, 1 (3.6) | Other, 5 (17.9) | Number of medications, 1 (3.6) |
Clinical history, 1 (3.6) | FIQ, 1 (3.6) | Duration of symptoms, 1 (3.6) | None listed, 7 (25.0) | Other, 7 (25.0) |
| Â | HAQ, 1 (3.6) | Global assessment, 1 (3.6) | Â | None listed, 12 (42.9) |
|  | Other†, 2 (6.9) | Number of medications, 1 (3.6) |  |  |
| Â | None listed, 1 (3.6) | Other, 4 (14.3 | Â | Â |